Aurinia (Formerly Known as Isotechnika Pharma Inc.)
5120 - 75th Street
246 articles with Aurinia (Formerly Known as Isotechnika Pharma Inc.)
Aurinia Pharmaceuticals Inc. today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc. today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.
AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule
Conference Call and webcast to follow
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities focused on raising awareness of lupus nephritis (LN)
Aurinia Pharmaceuticals Inc. announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes.
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Aurinia Pharmaceuticals Inc. announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference.
Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2017.
Aurinia announced that it has launched ALL IN, an educational program for people living with lupus nephritis (LN).
Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors
Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics.
Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
The Preliminary Shelf Prospectus and corresponding shelf registration statement, when made final or effective, will allow Aurinia to offer up to US$250,000,000 of common shares, warrants, subscription receipts, debt securities or any combination thereof during the 25-month period that the Preliminary Shelf Prospectus is effective.
Additionally, Aurinia was recently added to the MSCI Global Small Cap Indexes, which went into effect at close of November 30, 2017.
Cash of $182.4 million as of September 30, 2017.
At 4:30 p.m. Eastern Time Aurinia’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.